GCTK is an unshortable penny med tech stock. It is now overextended and fundamentals do not
support a move higher. Idea is on the chart. Overbought at this point and likely to fall by Friday
as traders take profits for the week.
Alpine is a biotech stock that had an earnings report beating estimates two weeks ago. It
is now reaching for all-time highs. That said, it is burning cash just slowing down the burn.
Both revenue and earnings showed remarkable improvement as compared with the previous
quarter. The bullish momentum of price and volume is obvious on the weeky chart with
the...
STRO on a 240 minute chart got trader interest out of earnings that were projected to be net
cash outflow into reported actual earnings. This is a remarkable turnaround. The RSI lines
surged. The predictive algorithm which relies on a lookback of the regression line for analysis
toward the future forecasts a move up much higher. I will take a long trade here...
Biotechnology is expected to be a hot subsector this year as healthcare recovered further from
the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for
diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend
with XBI pivoting to bullish back in early November. I add long positions when I...
VINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon
after a month of a slow climb from a news release that really did not amount to much. Insiders
are 25% of the shareholders and that may be the story here. This could be manipulation at its
finest. I have to wonder how many insiders bought how many shares and when the...
VTYX- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused
on advancing novel oral therapies that address a range of inflammatory diseases with significant
unmet medical need, announced today that it has entered into a stock purchase agreement for
the sale of 11,174,000 shares of its common stock at an offering price of...
BLUE a week ago had a bull run to gain 90% in 5 days and then reversed into a standard
Fibonacci retracement on the 30-minute chart, then in consolidation for a day or two getting
support from the mean anchored VWAP. The last trading day was a quick rise with momentum
in a bull flag. Earnings are coming. I will take another long trade on BLU into earnings....
MYO had impressive week gaining over 35%. It is a volatile penny biotechnology stock
with good earnings back in November new due for another report. On a 120 minute chart
with relative volatility and volume indicators and a volume profile added. The volume and
volativlty of this past week's move is obvious. Price gain has slowed on the approach to the
POC...
LEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle
or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the
historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of
the all high highs of 19 at the neckline of a head and shoulders back in 2018-2019,...
IOVA has doubled in February and broke out above its volume profile high volume area about
one week ago as it runs to earnings. Since it settled down two days ago into a relative side-
ways consolidation. I will take a long trade here for a pre-earnings play to presume that the
buying and bullish momentum will resume nearly immediately.
IBB looks to be in a Wyckoff Redistribution phase, with UTAD emerging currently.
On a larger time frame, looks as though a weekly H&S patter forming with the re-distribution section acting as the right shoulder.
My price target is $57, in line with the 1.618 fib extension.
SLN has appreciated 70% in the past month largly on the strength of an
earnings beat. Unlike many small cap biotechnology companies, SLN is
actually making money and beating analyst's estimates. On the 3O minute
chart, price is just below the POC line of the near term volume profile and
sitting on the dynamic support of a VWAP line. Strength lines are above...
IMGN had great earnings the last days of April and has been trending up ever since.
It is riding the upper Bollinger band consistently in this past wee. The volume spike
after earnings has subsided but ongoing volume is at about 5X the moving average of
early April and March. Increased volume supports price momentum. The volume spike
here is obvious and...
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Excellent bullish divergence on the monthly. Great time for a long trade on this asset that could attempt a retarget in the $ 240 zone.
NTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance.
"Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from...
On this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower...
This is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for...
